{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05237388",
            "orgStudyIdInfo": {
                "id": "Pro00108755"
            },
            "secondaryIdInfos": [
                {
                    "id": "R01MD016401-01",
                    "type": "NIH",
                    "link": "https://reporter.nih.gov/quickSearch/R01MD016401-01"
                }
            ],
            "organization": {
                "fullName": "Duke University",
                "class": "OTHER"
            },
            "briefTitle": "Janus Kinase-STAT Inhibition to Reduce APOL1 Associated Kidney Disease",
            "officialTitle": "Janus Kinase-STAT Inhibition to Reduce APOL1 Associated Kidney Disease",
            "acronym": "JUSTICE",
            "therapeuticArea": [
                "Nephrology and Renal Diseases"
            ],
            "study": "janus-kinase-stat-inhibition-to-reduce-associated-kidney-disease"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-03",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-04-20",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-03-31",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-03-31",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-01-31",
            "studyFirstSubmitQcDate": "2022-01-31",
            "studyFirstPostDateStruct": {
                "date": "2022-02-14",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-03-20",
            "lastUpdatePostDateStruct": {
                "date": "2024-03-21",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Duke University",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "National Institute on Minority Health and Health Disparities (NIMHD)",
                    "class": "NIH"
                },
                {
                    "name": "Eli Lilly and Company",
                    "class": "INDUSTRY"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this study is to determine if the drug, baricitinib, is safe and effective in reducing high levels of albumin in the urine (albuminuria) in African American/Blacks with APOL1- associated focal segmental glomerulosclerosis (FSGS) and non-diabetic APOL1-associated chronic kidney disease due to hypertension (HTN-CKD)."
        },
        "conditionsModule": {
            "conditions": [
                "Chronic Kidney Diseases"
            ],
            "keywords": [
                "APOL1",
                "focal segmental glomerulosclerosis (FSGS)"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "DOUBLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "INVESTIGATOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 75,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Baricitinib",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will take one pill of Baricitinib daily with their regular medications.",
                    "interventionNames": [
                        "Drug: Baricitinib"
                    ]
                },
                {
                    "label": "Placebo",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Participants will take a Baricitinib placebo pill matching Baricitinib daily with their regular medications.",
                    "interventionNames": [
                        "Drug: Placebo"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Baricitinib",
                    "description": "One pill daily",
                    "armGroupLabels": [
                        "Baricitinib"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Placebo",
                    "description": "Baricitinib placebo pill",
                    "armGroupLabels": [
                        "Placebo"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Percent change in albuminuria (UACR)",
                    "timeFrame": "Baseline, monthly for 6 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Percent change in eGFR as measured by blood test",
                    "timeFrame": "Baseline, monthly for 6 months"
                },
                {
                    "measure": "Percent change in urine CXCL 9-11 as measured by urine test",
                    "timeFrame": "Baseline, monthly for 6 months"
                },
                {
                    "measure": "Number of adverse events as measured by patient report",
                    "timeFrame": "Up to 6 months"
                },
                {
                    "measure": "Number of adverse events as measured by clinical lab value of hemoglobin less than 9.5g/dL",
                    "timeFrame": "Up to 6 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Adults 18-70 years\n* High Risk APOL1 genotype (i.e., G1G1, G2G2, or G1G2)\n* FSGS diagnosed by kidney biopsy or clinically diagnosed HTN-CKD\n* UACR \u2265300 mg/dL\n* Estimated glomerular filtration rate (eGFR) \u226526 ml/min/1.73 m2 at screening\n* Stable antihypertensive regimen for \u2265 1 month prior to enrolment\n* Able to provide written informed consent\n\nExclusion Criteria:\n\n* Diabetes\n* HIV\n* Sickle cell disease.\n* Tip variant of FSGS.\n* Systolic BP \\>180 mmHg or diastolic BP \\>90 mmHg based on average of 3 measurements.\n* Active serious viral, bacterial, fungal or parasitic infection.\n* Symptomatic herpes zoster infection within 12 weeks prior to study entry.\n* Positive hepatitis B surface antigen during screening (could enroll after treatment).\n* Previous kidney transplant.\n* History of chronic liver disease with the most recent available aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \\>1.5 times the ULN or the most recent available total bilirubin \u22651.5 times the ULN\n* Hemoglobin \\<10 g/dL.\n* Absolute lymphocyte count (ALC)\\<500cells/mm3 or absolute neutrophil count (ANC) \\< 1000 cells/mm3.\n* Pregnant or nursing at time of enrollment\n* Prior or current treatment with JAK inhibitor.\n* Current use of potent immunosuppressants such as abatacept, adalimumab, anakinra, azathioprine, certolizumab, etanercept, golimumab, infliximab, probenecid, rituximab, ruxolitinib, sarilumab, tofacitinib, or tocilizumab.\n* High dose corticosteroids (\\>10 mg per day of prednisone or equivalent) or an unstable dosing regimen of corticosteroids within 2 weeks of study entry or within 6 weeks of planned randomization.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "70 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Maurice Smith",
                    "role": "CONTACT",
                    "phone": "919 613 1386",
                    "email": "maurice.w.smith@duke.edu"
                },
                {
                    "name": "Opeyemi Olabisi, MD, PhD",
                    "role": "CONTACT",
                    "phone": "9196606987",
                    "email": "opeyemi.olabisi@duke.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Opeyemi Olabisi, MD",
                    "affiliation": "Duke University",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Duke Research at Pickett Road",
                    "status": "RECRUITING",
                    "city": "Durham",
                    "state": "North Carolina",
                    "zip": "27705",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Maurice Smith",
                            "role": "CONTACT",
                            "phone": "919-613-1386",
                            "email": "maurice.w.smith@duke.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 35.99403,
                        "lon": -78.89862
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000007674",
                    "term": "Kidney Diseases"
                },
                {
                    "id": "D000051436",
                    "term": "Renal Insufficiency, Chronic"
                }
            ],
            "ancestors": [
                {
                    "id": "D000014570",
                    "term": "Urologic Diseases"
                },
                {
                    "id": "D000052776",
                    "term": "Female Urogenital Diseases"
                },
                {
                    "id": "D000005261",
                    "term": "Female Urogenital Diseases and Pregnancy Complications"
                },
                {
                    "id": "D000091642",
                    "term": "Urogenital Diseases"
                },
                {
                    "id": "D000052801",
                    "term": "Male Urogenital Diseases"
                },
                {
                    "id": "D000051437",
                    "term": "Renal Insufficiency"
                },
                {
                    "id": "D000002908",
                    "term": "Chronic Disease"
                },
                {
                    "id": "D000020969",
                    "term": "Disease Attributes"
                },
                {
                    "id": "D000010335",
                    "term": "Pathologic Processes"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M10698",
                    "name": "Kidney Diseases",
                    "asFound": "Kidney Disease",
                    "relevance": "HIGH"
                },
                {
                    "id": "M9033",
                    "name": "Glomerulosclerosis, Focal Segmental",
                    "relevance": "LOW"
                },
                {
                    "id": "M26717",
                    "name": "Renal Insufficiency, Chronic",
                    "asFound": "Chronic Kidney Disease",
                    "relevance": "HIGH"
                },
                {
                    "id": "M26718",
                    "name": "Renal Insufficiency",
                    "relevance": "LOW"
                },
                {
                    "id": "M17319",
                    "name": "Urologic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M2875",
                    "name": "Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M27093",
                    "name": "Female Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14127",
                    "name": "Pregnancy Complications",
                    "relevance": "LOW"
                },
                {
                    "id": "M8399",
                    "name": "Female Urogenital Diseases and Pregnancy Complications",
                    "relevance": "LOW"
                },
                {
                    "id": "M27095",
                    "name": "Male Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M6147",
                    "name": "Chronic Disease",
                    "relevance": "LOW"
                },
                {
                    "id": "M22700",
                    "name": "Disease Attributes",
                    "relevance": "LOW"
                },
                {
                    "id": "T1303",
                    "name": "Chronic Graft Versus Host Disease",
                    "relevance": "LOW"
                },
                {
                    "id": "T2357",
                    "name": "Focal Segmental Glomerulosclerosis",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        }
    },
    "hasResults": false
}